Enveda Raises $311M at $2B Valuation to Advance AI-Discovered Drugs

Enveda, a biotech startup using AI to discover drugs from natural sources, has raised $311 million in a Series E funding round at a $2 billion valuation. The company is advancing multiple AI-discovered drug candidates into clinical trials, marking a significant milestone for the intersection of AI and biotechnology.

Series E Funding at $2 Billion Valuation

Enveda, a biotech startup specializing in AI-driven drug discovery, has secured $311 million in a Series E funding round. According to TechCrunch, the round doubles the company’s valuation to $2 billion, up from its valuation 12 months ago.

The funding was led by Catalio Capital Management, with participation from Iconiq and other undisclosed investors.

AI-Driven Drug Discovery from Natural Sources

Enveda’s approach focuses on harnessing potential medicines from plants and microbes, rather than synthesizing them from scratch in a lab. The company leverages AI and other technologies to accelerate the discovery process, a method that sets it apart from traditional biotech firms.

As reported by TechCrunch, Enveda is currently advancing multiple AI-discovered drug candidates into human clinical trials. These include treatments targeting severe skin conditions and a therapy designed to help maintain weight loss after stopping GLP-1 medications.

Founder Background and Company Origins

Enveda was founded in 2019 by Viswa Colluru, who was an early employee at Recursion Pharmaceuticals, another company in the AI-driven drug discovery space. The startup’s focus on nature-derived medicines aligns with a growing interest in alternative sources for therapeutic compounds.

Despite the hype around AI in drug discovery, TechCrunch notes that no AI-discovered drug has yet received FDA approval. Enveda’s progress in clinical trials could serve as a critical test for the viability of AI in this field.

What this means

LazyFounders analysis — our interpretation, not reported fact.

Enveda’s $311 million Series E and $2 billion valuation reflect growing investor confidence in AI-driven drug discovery, particularly from natural sources. While AI has yet to produce an FDA-approved drug, the fact that Enveda is already advancing multiple candidates into clinical trials is a strong signal for the sector. For founders and operators, this deal underscores the potential of combining AI with traditional biotech approaches—especially in high-demand areas like dermatology and metabolic health. However, the pressure to deliver clinical success is intensifying, as investors will be watching closely to see if AI can finally translate into approved therapies.

Key takeaways

• Enveda’s $2 billion valuation doubles its value from 12 months ago, highlighting rapid growth in AI-driven biotech.
• The startup focuses on discovering drugs from natural sources, differentiating itself from traditional lab-based synthesis.
• AI hasn’t yet produced an FDA-approved drug, but Enveda’s clinical trials could be a critical test for the technology.
• The funding round was led by Catalio Capital Management, with participation from Iconiq and other investors.
• Enveda’s founder, Viswa Colluru, brings experience from Recursion Pharmaceuticals, a key player in the AI-drug discovery space.

FAQ

What does Enveda do?

Enveda is a biotech startup that uses AI to discover potential drugs from natural sources like plants and microbes, rather than synthesizing them in a lab.

Who led Enveda’s Series E funding round?

The $311 million Series E funding round was led by Catalio Capital Management, with participation from Iconiq and other investors.

What is Enveda’s valuation after the Series E round?

Enveda’s valuation doubled to $2 billion following the Series E funding round.

Has AI yet produced an FDA-approved drug?

No, as of now, no AI-discovered drug has received FDA approval, though Enveda and other companies are working to change that.

What clinical trials is Enveda conducting?

Enveda is testing multiple AI-discovered drug candidates in clinical trials, including treatments for severe skin conditions and a therapy to help maintain weight loss after stopping GLP-1 medications.

Related on LazyFounders

• More startup news